首页|Efficacy ofBRAF-InhibitorTherapy in BRAF(V600E)-MutatedAdult Langerhans Cell Histiocytosis

Efficacy ofBRAF-InhibitorTherapy in BRAF(V600E)-MutatedAdult Langerhans Cell Histiocytosis

扫码查看
原文链接
  • NSTL
  • Wiley
Langerhans cell histiocytosis (LCH) is a rare histiocytic neoplasm. To date, there is a lack of U.S. Food and Drug Administration-approved treatments in adult LCH to establish optimal first-line therapy. We conducted a retrospective, single-center case series evaluating the use of BRAF inhibitors in adult patients withBRAF(V600E)- LCH proven by biopsy. Our case series is the first to report the use of BRAF inhibitors as first-line therapy in adults with LCH. We also report the efficacy with single-agent dabrafenib in adult LCH. All but one of our patients had favorable response to targeted therapy.

VemurafenibDabrafenibTargeted therapyHistiocytosis

Hazim, Antonious Z.、Ruan, Gordon J.、Ravindran, Aishwarya、Abeykoon, Jithma P.、Scheckel, Caleb、Vassallo, Robert、Ryu, Jay H.、Tobin, W. Oliver、Koster, Matthew J.、Bennani, N. Nora、Rech, Karen L.、Young, Jason R.、Shah, Mithun V.、Goyal, Gaurav、Go, Ronald S.

展开 >

Mayo Clin, Div Internal Med, Rochester, MN USA

Mayo Clin, Div Lab Med & Pathol, Rochester, MN USA

Mayo Clin, Div Hematol, 200 First St SW, Rochester, MN 55905 USA

Mayo Clin, Div Pulm & Crit Care Med, Rochester, MN USA

Mayo Clin, Div Neurol, Rochester, MN USA

Mayo Clin, Div Rheumatol, Rochester, MN USA

Mayo Clin, Div Radiol, Rochester, MN USA

Mayo Clin, Mayo Clin Histiocytosis Working Grp, Dept Res, Rochester, MN USA

展开 >

2020

10.1002/onco.13541

The oncologist

The oncologist

ISSN：1083-7159
年,卷(期)：2020.25(12)
  • 12
  • 13